Duchenne Muscular Dystrophy is an indication for drug development with over 200 pipeline drugs currently active. According to GlobalData, preregistered drugs for Duchenne Muscular Dystrophy have a 87.5% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Duchenne Muscular Dystrophy compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Duchenne Muscular Dystrophy overview
Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. Risk factors include gender and family history. Treatments include steroid medication, respiratory therapy, and surgery.
For a complete picture of PTSR and LoA scores for drugs in Duchenne Muscular Dystrophy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.